4.5 Article

Sarcopenia: Pharmacology of Today and Tomorrow

Journal

Publisher

AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/jpet.112.191759

Keywords

-

Funding

  1. National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases [RC2-AR058962]
  2. National Institutes of Health National Institute on Aging [1P01-AG039355-01A1]
  3. Missouri Life Sciences Research Board
  4. Department of Health Services-Clay County Senior Services

Ask authors/readers for more resources

Sarcopenia remains largely undiagnosed and undertreated because of the lack of a universally accepted definition, effective ways to measure it, and identification of the outcomes that should guide treatment efficacy. An ever-growing number of clinicians and researchers along with funding and regulatory agencies have gradually recognized that sarcopenia is a human condition that requires both prevention and treatment. In this article, we review sarcopenia and its common and less known pharmacological treatments, attempt to define sarcopenia in its broader context, and present some new ideas for potential future treatment for this devastating condition.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available